Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Changes in the sex ratio are a good indicator of changes in MS incidence - No

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Serum and cerebrospinal fluid neurofilament levels predict longitudinal atrophy of the cervical spinal cord in progressive MS

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. MAIT cell subtypes in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Disentangling white-matter damage from physiological fibre orientation dispersion in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Intoxicationer og ernæringsdeficit

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisning

Vis graf over relationer

BACKGROUND: Dimethyl fumarate (DMF) is a disease-modifying therapy used for patients with relapsing-remitting multiple sclerosis (RRMS). B cells are important contributors to the pathogenesis of RRMS, where they regulate the inflammatory immune responses and participate in development of lesions in the central nervous system (CNS). The impact of DMF on B cell subpopulations remains incompletely understood.

OBJECTIVES: In this study, we evaluated the effects of DMF on B cell subpopulations and their effector functions.

METHODS: Blood from 21 DMF-treated and 18 untreated patients with RRMS was analyzed by flow cytometry.

RESULTS: We found that DMF reduces the frequency of circulating antigen-experienced B cells, a reduction likely related to a reduced frequency of follicular helper T (TFH) cells and an increased frequency of follicular regulatory T (TFR) cells. Studying the impact of monomethyl fumarate (MMF), the primary metabolite of DMF, on B cell effector function in vitro showed that MMF increased the frequency of transforming growth factor (TGF)-β-producing B cells and decreased the frequency of B cells secreting lymphotoxin (LT)-α, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and to a lesser extent IL-10.

CONCLUSION: In summary, these data suggest an anti-inflammatory role of DMF and its metabolite MMF on the B cell compartment.

OriginalsprogEngelsk
TidsskriftMultiple sclerosis
Vol/bind25
Udgave nummer9
Sider (fra-til)1289-1297
Antal sider9
ISSN1352-4585
DOI
StatusUdgivet - aug. 2019

ID: 58577613